The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1658
September 5, 2022
View Complete Issue         Table of Contents 2019 
Nalmefene Returns for Reversal of Opioid Overdose
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nalmefene Returns for Reversal of Opioid Overdose
September 5, 2022 (Issue: 1658)
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex, the reference product, was withdrawn from the market in 2008 for commercial...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nalmefene Returns for Reversal of Opioid Overdose
Article code: 1658c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.